Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 27, Issue 11, Pages 1183-1199
Publisher
Informa UK Limited
Online
2017-08-02
DOI
10.1080/13543776.2017.1360285
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor
- (2017) Lyamin Z. Bendjeddou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Kinase targets in CNS drug discovery
- (2017) Hendra Gunosewoyo et al. Future Medicinal Chemistry
- Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma
- (2017) Qingqing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Regulatory T Cells: Central Concepts from Ontogeny to Therapy
- (2017) Bernard Khor TRANSFUSION MEDICINE REVIEWS
- Inhibition of DYRK1A Stimulates Human β-Cell Proliferation
- (2016) Ercument Dirice et al. DIABETES
- DYRK1A: A Promising Drug Target for Islet Transplant–Based Diabetes Therapies
- (2016) Bengt-Frederik Belgardt et al. DIABETES
- A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition
- (2016) Hyeongki Kim et al. Disease Models & Mechanisms
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- (2016) Peng Wu et al. DRUG DISCOVERY TODAY
- Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors
- (2016) Christophe Labrière et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- DYRK1A inhibition as potential treatment for Alzheimer’s disease
- (2016) Silvia Stotani et al. Future Medicinal Chemistry
- An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases
- (2016) Apirat Chaikuad et al. JOURNAL OF MEDICINAL CHEMISTRY
- Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules
- (2016) Ulli Rothweiler et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial
- (2016) Rafael de la Torre et al. LANCET NEUROLOGY
- Synthesis of Thiazolo[5,4-f]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases
- (2016) Damien Hédou et al. MOLECULES
- Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the Hügershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation
- (2016) Damien Hédou et al. MOLECULES
- Phosphorylation of β-Tubulin by the Down Syndrome Kinase, Minibrain/DYRK1a, Regulates Microtubule Dynamics and Dendrite Morphogenesis
- (2016) Kassandra M. Ori-McKenney et al. NEURON
- A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma
- (2016) Aneesha Radhakrishnan et al. Scientific Reports
- DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome
- (2016) Arnaud Duchon et al. Frontiers in Behavioral Neuroscience
- Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis
- (2015) So Masaki et al. BIOORGANIC & MEDICINAL CHEMISTRY
- DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model
- (2015) N. Kurabayashi et al. EMBO REPORTS
- Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors
- (2015) Ulli Rothweiler et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The ins and outs of selective kinase inhibitor development
- (2015) Susanne Müller et al. Nature Chemical Biology
- DYRK1A overexpression in pancreatic ductal adenocarcinoma contributes to tumor growth
- (2015) Jeroni Luna et al. PANCREATOLOGY
- DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications
- (2015) Ramzi Abbassi et al. PHARMACOLOGY & THERAPEUTICS
- Allosteric small-molecule kinase inhibitors
- (2015) Peng Wu et al. PHARMACOLOGY & THERAPEUTICS
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Inhibition of DYRK1A and GSK3B induces human β-cell proliferation
- (2015) Weijun Shen et al. Nature Communications
- The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells
- (2015) Bernard Khor et al. eLife
- The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation
- (2014) Ulf Soppa et al. CELL CYCLE
- DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies
- (2014) Walter Becker et al. CNS & Neurological Disorders-Drug Targets
- Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors
- (2014) Oussama Dehbi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part II
- (2014) Alicia Foucourt et al. MOLECULES
- Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part I
- (2014) Alicia Foucourt et al. MOLECULES
- DYRK1A-mediated phosphorylation of GluN2A at Ser1048 regulates the surface expression and channel activity of GluN1/GluN2A receptors
- (2014) Cristina Grau et al. Frontiers in Cellular Neuroscience
- Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors
- (2013) Kevin Anderson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
- (2013) Natividad Pozo et al. JOURNAL OF CLINICAL INVESTIGATION
- Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity
- (2013) Stéphanie Gourdain et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recent advances in the synthesis and properties of 4-, 5-, 6- or 7-azaindoles
- (2013) Jean-Yves Mérour et al. TETRAHEDRON
- Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?
- (2012) Breland Smith et al. ACS Chemical Neuroscience
- Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors
- (2012) Gregory D. Cuny et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B
- (2012) Tania Tahtouh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors
- (2012) Julien Debray et al. MOLECULAR DIVERSITY
- Library-based Discovery of DYRK1A/CLK1 Inhibitors from Natural Product Extracts
- (2012) Patrick Grabher et al. PLANTA MEDICA
- Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)
- (2011) Andrew S. Rosenthal et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents
- (2011) Pamela Kassis et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis, Protein Kinase Inhibitory Potencies, and in Vitro Antiproliferative Activities of Meridianin Derivatives
- (2011) Francis Giraud et al. JOURNAL OF MEDICINAL CHEMISTRY
- Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing
- (2011) Mansour Debdab et al. JOURNAL OF MEDICINAL CHEMISTRY
- β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites
- (2011) Danielle Frost et al. PLoS One
- DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles
- (2010) Sergi Aranda et al. FASEB JOURNAL
- MNB/DYRK1A as a multiple regulator of neuronal development
- (2010) Francisco J. Tejedor et al. FEBS Journal
- Activation, regulation, and inhibition of DYRK1A
- (2010) Walter Becker et al. FEBS Journal
- The role of DYRK1A in neurodegenerative diseases
- (2010) Jerzy Wegiel et al. FEBS Journal
- Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer
- (2010) Fabrice Pierre et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
- (2010) Yasushi Ogawa et al. Nature Communications
- Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk)
- (2009) Bryan T. Mott et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The selectivity of inhibitors of protein kinase CK2: an update
- (2008) Mario A. Pagano et al. BIOCHEMICAL JOURNAL
- Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex†
- (2008) Aude Echalier et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More